Dashboard/MRNA/mRNA-1083/event

ReadoutTopline Readoutreported

mRNA-1083 P304 Flu+COVID Phase 3 Topline

MRNA·mRNA-1083·Seasonal Influenza·

Phase 3

·NCT05955807

reported

APR 15

2026

EXACT

Takeaway

Reported 2026-04-15: combination flu + COVID vaccine met non-inferiority vs. licensed comparators in adults ≥50. mRNA-1083 is Moderna’s first non-COVID respiratory commercial candidate and the basis for a planned BLA filing.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAcombination flu + COVID-19 mRNA vaccine

mRNA-1083 is Moderna's combination influenza and COVID-19 vaccine, designed as a single annual shot protecting against both respiratory viruses simultaneously. The vaccine delivers mRNA instructions encoding influenza hemagglutinin antigens alongside the SARS-CoV-2 spike protein, training the immune system to defend against both pathogens in one dose. A Phase 3 trial in adults aged 50 and older reported positive non-inferiority results versus licensed comparators in April 2026, supporting a planned BLA filing as Moderna's first non-COVID respiratory commercial candidate.

Indication

Vaccines

Seasonal Influenza

MeSH · D007251

No primer in glossary yet.

Trial

completed

NCT05955807 ↗

P304: Phase 3 Efficacy Study of mRNA-1083 (Flu+COVID)

Glossary · what this readout is measuring

1 term detected in the takeaway

BLAregulatory
Biologics License Application
FDA submission for approval of a biologic (antibody, gene/cell therapy, vaccine). Same clock as NDA.

Competitive landscape

1 peer in Vaccines · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
mRNA-1647	MRNA	mRNA	pentavalent CMV vaccine		READOUT · Dec 26

Prior MRNA reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

+32.0%

Median 1M move

+43.9%

Positive outcomes

1/ 1

100%

Negative outcomes

0/ 1

Date	Headline	Outcome	1W	1M	6M
Apr 2026	mRNA-1083 P304 Flu+COVID Phase 3 Topline	positive	+32.0%	+43.9%	+28.7%

Historical MRNA stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 100%.

Disclosure trail

1 observation · sorted by confidence

Apr 15, 2026·15d agopinned · highest confidence
HIGH conf8-K
top claim
APR 152026
EXACT
“Moderna today announced positive topline results from the Phase 3 P304 trial of mRNA-1083, a combination flu and COVID vaccine, demonstrating non-inferior immune responses versus separate licensed comparators in adults ≥50.”
conf 98%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.